A randomized, double blind, controlled, multi center study of Ilaparazole in the treatment of reflux esophagitis - Phase III clinical trial
Contemporary Clinical Trials Mar 16, 2018
Xue Y, et al. - The intention of experts was to determine the suitable dose of Ilaparazole in the treatment of reflux esophagitis. It was disclosed that the efficacy and safety of Ilaparazole (10 mg/day) in treating reflux esophagitis was similar to esomeprazole (40 mg/day). Findings displayed that Ilaparazole (10 mg/day) could be used in the treatment of esophagitis.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries